Dasatinib and Quercetin Reach the Brain in Early Alzheimer's Patients
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
20 articles
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
Single-cell analysis reveals how the flavonoid fisetin may reduce neuroinflammation in Alzheimer's disease by targeting specific astrocyte subgroups.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
New research maps a stress-signaling cascade linking p53 activation to brain inflammation and depression, with curcumin interrupting it.
New review reveals how combining citicoline, CoQ10, and other agents may protect retinal cells better than single treatments.
High-dose niacin revived suppressed immune cells in glioblastoma patients, with 82% showing no progression at 6 months โ 28% better than expected.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
New research reveals statins could reduce dementia risk by 85% in genetically susceptible individuals, offering personalized prevention.
Review reveals how PQQ supplement protects neurons via antioxidant, mitochondrial, and anti-inflammatory mechanisms in neurodegenerative diseases.
A traditional Chinese herbal formula improves cognition and cerebrovascular health in Alzheimer's mice by activating the LKB1-AMPK-SIRT1 autophagy cascade.
DPCPX treatment enhanced neurogenesis and improved motor/memory function in stroke recovery studies using advanced PET imaging.
New research reveals why cytarabine chemotherapy causes severe cerebellar toxicity while similar drugs don't.
Nicotinamide riboside prevents moyamoya-like brain vessel blockages by fixing cellular energy production in smooth muscle cells.
A Cochrane meta-analysis of 8 RCTs finds most pharmacological treatments fail to improve ataxia scores, though upper limb dexterity may benefit.
A roundup of recent FDA brain-health approvals including lecanemab's full Alzheimer's approval and a new glioma drug.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
A home-based walking and resistance program improved attention and reduced observable cognitive decline in chemotherapy patients over 6 weeks.
A small trial found tocilizumab, an anti-inflammatory drug, cut depression remission rates better than SSRIs by targeting IL-6, not brain chemistry.
60-patient trial explores whether metformin, combined with standard therapy, could slow Parkinson's progression through metabolic pathways.